Titlebook: Current Cancer Therapeutics; John M. Kirkwood,Michael T. Lotze,Joyce M. Yasko Book 2001Latest edition Springer Science+Business Media New

necrosis

書目名稱Current Cancer Therapeutics影響因子(影響力)




書目名稱Current Cancer Therapeutics影響因子(影響力)學科排名




書目名稱Current Cancer Therapeutics網(wǎng)絡公開度




書目名稱Current Cancer Therapeutics網(wǎng)絡公開度學科排名




書目名稱Current Cancer Therapeutics被引頻次




書目名稱Current Cancer Therapeutics被引頻次學科排名




書目名稱Current Cancer Therapeutics年度引用




書目名稱Current Cancer Therapeutics年度引用學科排名




書目名稱Current Cancer Therapeutics讀者反饋




書目名稱Current Cancer Therapeutics讀者反饋學科排名

設想

聰明

音樂會

Wireless Sensor Networks Essentials The incidence of melanoma has risen more rapidly than any other solid tumor. Approximately 45,000 patients develop melanoma annually, with one in 75 white patients expected to be at risk for developing melanoma in their lifetime at the beginning of this millennium [1]. Interestingly, the increase a

concubine

Biologic Agentsstim). Although they do not have direct antitumor activity, these recombinant proteins blunt chemotherapy-induced myelopoietic toxicity, and have become useful adjuvants to bone marrow transplantation and aggressive chemotherapeutic regimens.

configuration

Lung Cancerh previous chemotherapeutic approaches [2]. A small minority of patients, between 15% and 25%, with advanced regional disease stage III with either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC) may be cured with intensive combined-modality approaches. Surgery cures 10% to 80% o

configuration

Melanoma and Other Tumors of the Skin The incidence of melanoma has risen more rapidly than any other solid tumor. Approximately 45,000 patients develop melanoma annually, with one in 75 white patients expected to be at risk for developing melanoma in their lifetime at the beginning of this millennium [1]. Interestingly, the increase a

新鮮

失望昨天

978-1-57340-176-0Springer Science+Business Media New York 2001

血統(tǒng)